The abstract is read at the publisher; the summary is JClub's.
Perioperative toripalimab plus chemotherapy improved investigator-assessed event-free survival in resectable stage II/III non-small-cell lung cancer, with stratified HR 0.52 at final analysis.
- Why it matters: Interim results in stage III resectable NSCLC needed confirmation for durability and to establish overall outcomes across stage II and III patients.
- What they did: In a randomized trial in China (N=501; toripalimab n=250, placebo n=251), patients received neoadjuvant chemotherapy plus toripalimab or placebo, then adjuvant therapy and maintenance up to 13 cycles.
- The result: At median follow-up of 48.2 months, EFS was not reached with toripalimab versus 20.2 months with placebo; major pathological response was 47% versus 9% (P<0.0001), and overall survival improved (HR 0.66, P=0.0072) with no new safety signals.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.